RELX Technology's Stock Price Drops in Midday Trading

Business by 2FIRSTS.ai
Dec.22.2023
RELX Technology's Stock Price Drops in Midday Trading
RELX Technology, an e-cigarette manufacturer, saw a 2.9% drop in stock price during Thursday's midday trading.

According to market trading website watchlistnews, the stock price of e-cigarette manufacturer RELX Technology dropped by 2.9% during Thursday's midday trading session. The stock reached a low trading price of $1.94 per share and closed at $1.98 per share. During the midday session, there were a total of 1,728,733 shares traded, which is a 79% decrease compared to the average trading volume of 8,406,188 shares. The previous closing price was $2.04.

 

Over the past 50 days, the average price of the company's stock has been $1.90, while the 200-day moving average price stands at $1.72.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Black Friday Meets Thanksgiving: Multiple E-Cigarette Brands Launch Discounts and Giveaways Across North America and Europe
Black Friday Meets Thanksgiving: Multiple E-Cigarette Brands Launch Discounts and Giveaways Across North America and Europe
As Black Friday, Cyber Monday and Thanksgiving shopping season arrive, e-cigarette brands such as OXVA and VAPORESSO, together with online retail platforms, have launched concentrated discount and giveaway campaigns running from mid-November to early December. Promotions include tiered reductions, sitewide discounts, bundle deals and interactive prize draws, covering North America, the UK and parts of the EU market.
Nov.26 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
Product | FLONQ Parent Company Launches New Vaping Brand ROQY: Two Hybrid-Nicotine Devices Debut in Russia
Product | FLONQ Parent Company Launches New Vaping Brand ROQY: Two Hybrid-Nicotine Devices Debut in Russia
Alfabet Labs, the parent company of FLONQ, has recently launched its new vaping brand ROQY in Russia, debuting two products: ROQY L and ROQY M. Both devices use a hybrid nicotine formulation combining nicotine salts and freebase nicotine and are each available in 19 flavors. The two products are now on sale via the official ROQY website as well as multiple online and offline retailers across Russia.
Nov.19 by 2FIRSTS.ai
State Tobacco Monopoly Administration Chief Meets with President of South Korean Tobacco Company Wang Gongcheng also in attendance; friendly talks held between the two parties.
State Tobacco Monopoly Administration Chief Meets with President of South Korean Tobacco Company Wang Gongcheng also in attendance; friendly talks held between the two parties.
State Tobacco Monopoly Administration director Zhang Jianmin met with Korean Tobacco Company president Fang Jingwan in Beijing on October 31.
Nov.03 by 2FIRSTS.ai
Lithuanian Schools Install Vape Detectors as Teen Vaping Surges
Lithuanian Schools Install Vape Detectors as Teen Vaping Surges
Over 30 Lithuanian schools have installed smart vape detectors to curb rising teen e-cigarette use. WHO data show Lithuania ranks worst among 44 countries, with 60% of 15-year-olds having tried vaping. The system alerts staff to smoke and noise changes, helping schools reduce on-campus vaping cases.
Oct.27 by 2FIRSTS.ai
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.
Nov.24 by 2FIRSTS.ai